Latest news
EUSA Pharma announces acquisition of global rights to SYLVANT® (siltuximab) from Janssen Sciences Ireland UC for $115 million
Read more
We are passionate and committed to make our products globally available to enable patients to live and embrace life
Who we are
We are a dynamic, global speciality pharmaceutical company committed to bringing innovative medicines to patients.
Therapy Areas
Our therapy areas, which focus on oncology and rare diseases, help make a meaningful difference to patients’ lives.
Careers
We are constantly looking for highly talented individuals who, like us, are passionate and committed to helping patients live and embrace life.